## Glen J Pearson

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8751676/glen-j-pearson-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66 2,677 18 51 h-index g-index citations papers 82 3,210 1.9 4.47 L-index ext. citations avg, IF ext. papers

#	Paper	IF	Citations
66	Omega-3 fatty acids for cardiovascular disease prevention: A practice tool for pharmacists <i>Canadian Pharmacists Journal</i> , <b>2022</b> , 155, 169-174	1.3	
65	Lipid therapy: A new whiteboard video for patient education. <i>Canadian Pharmacists Journal</i> , <b>2021</b> , 154, 175-178	1.3	1
64	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1129-1150	3.8	62
63	The Canadian Consensus Working Group Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. <i>Contemporary Cardiology</i> , <b>2020</b> , 137-150	0.1	
62	Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery. <i>Pharmacotherapy</i> , <b>2020</b> , 40, 116-124	5.8	O
61	Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis. <i>Annals of Pharmacotherapy</i> , <b>2019</b> , 53, 997-1004	2.9	2
60	Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. <i>CJC Open</i> , <b>2019</b> , 1, 297-304	2	
59	Prevention and management of statin adverse effects: A practical approach for pharmacists. <i>Canadian Pharmacists Journal</i> , <b>2018</b> , 151, 179-188	1.3	9
58	Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 888-895	3	8
57	A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipients. <i>Transplantation Reviews</i> , <b>2018</b> , 32, 151-156	3.3	3
56	Comment: Should an LDL Cholesterol Target-Based Approach Be Readopted?. <i>Annals of Pharmacotherapy</i> , <b>2018</b> , 52, 706-707	2.9	1
55	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. <i>American Journal of Health-System Pharmacy</i> , <b>2018</b> , 75, 747-754	2.2	2
54	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1553-1563	3.8	58
53	Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 1600-1605	3.8	18
52	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. <i>Cmaj</i> , <b>2018</b> , 190, E1192-E1206	3.5	16
51	The Past, the Present, and a Very Bright Future. Canadian Journal of Hospital Pharmacy, 2017, 70, 328	0.5	
50	2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. <i>Canadian Pharmacists Journal</i> , <b>2017</b> , 150, 243-250	1.3	5

49	The Pursuit of Professional Practice Excellence and the Achievement of Peer Recognition. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2017</b> , 70, 92	0.5	
48	A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study). <i>Canadian Pharmacists Journal</i> , <b>2016</b> , 149, 283-	- <del>29</del> 3	36
47	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1263-1282	3.8	543
46	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, S35-65	3.8	138
45	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. <i>Canadian Family Physician</i> , <b>2016</b> , 62, 32-7	0.9	26
44	Evaluation of the Management of Hyperlipidemia and Hypertension in an Outpatient Cardiac Transplant Clinic. <i>Pharmacology &amp; Pharmacy</i> , <b>2016</b> , 07, 71-80	0.3	
43	New Antilipid Drugs: Do the Known Benefits Justify the Expense?. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2016</b> , 69, 323-6	0.5	
42	Belonging to CSHP-An Investment in Your Future and That of Hospital Pharmacy!. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2016</b> , 69, 180	0.5	
41	Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 643-50	5.8	55
40	Professional use of social media by pharmacists. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2015</b> , 68, 22-7	0.5	15
39	A Change of Seasons-A New Beginning!. Canadian Journal of Hospital Pharmacy, 2015, 68, 436	0.5	
38	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. <i>Canadian Pharmacists Journal</i> , <b>2015</b> , 148, 21-8	1.3	4
37	A new year-time for reconciliation. Canadian Journal of Hospital Pharmacy, 2015, 68, 96	0.5	1
36	Une nouvelle ann : l'heure est au bilan. Canadian Journal of Hospital Pharmacy, 2015, 68, 95	0.5	
35	Death to the Print Format-But Let Us Not Forget Our Past. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2015</b> , 68, 494	0.5	
34	Adverse drug reactions: The importance of maintaining pharmacovigilance. <i>Canadian Pharmacists Journal</i> , <b>2014</b> , 147, 233-8	1.3	2
33	The art of planning. Canadian Journal of Hospital Pharmacy, 2014, 67, 324	0.5	
32	Cardiovascular MRI predicts 5-year adverse clinical outcome in heart transplant recipients. <i>American Journal of Transplantation</i> , <b>2014</b> , 14, 2055-61	8.7	19

31	Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery. <i>Pharmacotherapy</i> , <b>2014</b> , 34, 464-72	5.8	7
30	Non-Immunosuppressant Medication Use in Heart Transplant Patients: A Guide for Pharmacists. <i>Pharmacology &amp; Pharmacy</i> , <b>2014</b> , 05, 950-958	0.3	
29	Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1553-68	3.8	126
28	2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 151-67	3.8	545
27	Research Grants from the CSHP Research and Education Foundation. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2012</b> , 65, 152	0.5	
26	An evaluation of teaching physical examination to pharmacists. <i>Canadian Pharmacists Journal</i> , <b>2012</b> , 145, 174-179.e1	1.3	17
25	A systematic review of the evidence for pharmacist care of patients with dyslipidemia. <i>Pharmacotherapy</i> , <b>2012</b> , 32, 222-33	5.8	60
24	Frequency of intensive statin therapy in patients with acute coronary syndrome admitted to a tertiary care center. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1-5	3	7
23	Low-dose ASA Use for Primary Prevention of Cardiovascular Disease in Patients without Diabetes: When Should You Recommend it? A Case-Based Approach. <i>Canadian Pharmacists Journal</i> , <b>2011</b> , 144, 278-286.e1	1.3	
22	Secondary stroke prevention: practice patterns in a tertiary care stroke service. <i>Canadian Journal of Neurological Sciences</i> , <b>2010</b> , 37, 245-51	1	5
21	Prescribing by Pharmacist's and Collaborative Care: Are We Ready to Accept the Baton and Get in the Race?. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2010</b> , 63, 59	0.5	
20	Macrolide Antibiotics and Calcineurin Inhibitors: Avoiding a Far too Common Drug Interaction in Transplant Patients. <i>Canadian Pharmacists Journal</i> , <b>2009</b> , 142, 68-70	1.3	1
19	Colchicine for the primary and secondary prevention of pericarditis: an update. <i>Annals of Pharmacotherapy</i> , <b>2009</b> , 43, 2075-81	2.9	8
18	Monitoring of mycophenolate mofetil in orthotopic heart transplant recipientsa systematic review. <i>Transplantation Reviews</i> , <b>2009</b> , 23, 171-7	3.3	6
17	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. <i>Canadian Journal of Cardiology</i> , <b>2009</b> , 25, 567-79	3.8	567
16	Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease by Pharmacists. <i>Canadian Pharmacists Journal</i> , <b>2008</b> , 141, S11-S16	1.3	5
15	Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 1127-35	4.4	2
14	Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 133-7	2.9	9

## LIST OF PUBLICATIONS

13	Evolution in the practice of pharmacynot a revolution!. <i>Cmaj</i> , <b>2007</b> , 176, 1295-6	3.5	45
12	New advances in antirejection therapy. <i>Current Opinion in Cardiology</i> , <b>2007</b> , 22, 117-22	2.1	14
11	The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 939-45	3.8	5
10	Pretransplant diabetes, not donor age, predicts long-term outcomes in cardiac transplantation.  Journal of Cardiac Surgery, <b>2006</b> , 21, 117-24	1.3	12
9	Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). <i>Pharmacotherapy</i> , <b>2005</b> , 25, 110-5	5.8	23
8	Comment: supratherapeutic response to ezetimibe administered with cyclosporine. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 2141; author reply 2142	2.9	1
7	Supratherapeutic response to ezetimibe administered with cyclosporine. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 1561-5	2.9	32
6	Use of OTC and herbal products in patients with cardiovascular disease. <i>Annals of Pharmacotherapy</i> , <b>2003</b> , 37, 899-904	2.9	46
5	The importance of in-hospital statin therapy for patients with acute coronary syndromes. <i>Pharmacotherapy</i> , <b>2003</b> , 23, 506-13	5.8	13
4	Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2003</b> , 28, 329-38	2.2	16
3	Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 390-4	3	35
2	Assessment of new onset postcoronary artery bypass surgery atrial fibrillation: current practice pattern review and the development of treatment guidelines. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2002</b> , 27, 21-37	2.2	6
1	Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes. Journal of Clinical Pharmacy and Therapeutics, 2001, 26, 351-61	2.2	14